SCHEMBL5402834

SCHEMBL5402834

CN(C(=O)c1ccccc1-c1ccccc1C(=O)N(CCC(=O)O)CCc1ccccn1)c1ccccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.43
HCRTR2 O43614 3/20 0.43
KDM4E B2RXH2 4/20 0.40
RAF1 P04049 1/20 0.40
MAP2K1 Q02750 1/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
TSHR P16473 1/20 0.38
ALDH1A1 P00352 2/20 0.38
HIF1A Q16665 2/20 0.38
HSD11B1 P28845 1/20 0.38
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5403476 0.91 FFAR1 (0.41) HCRTR1HCRTR2POLBLMNAHTT
SCHEMBL5399576 0.88 FFAR1 (0.40) HCRTR1HCRTR2KDM4ELMNACYP1A2
SCHEMBL5409818 0.88 FFAR1 (0.45) NPC1POLBRAB9ALMNATSHR
SCHEMBL5414051 0.87 KMT2A (0.46) HCRTR1HCRTR2CYP3A4TDP1MEN1
SCHEMBL5399342 0.87 KDM4E (0.41) HCRTR1HCRTR2KDM4EALDH1A1MEN1
SCHEMBL5397881 0.85 TRPV1 (0.41) HCRTR1HCRTR2KDM4ERAF1MAP2K1
SCHEMBL5399135 0.85 CYP2D6 (0.43) KDM4ENPC1POLBRAB9ALMNA
SCHEMBL5404093 0.85 HCRTR1 (0.40) HCRTR1HCRTR2KDM4ERAF1MAP2K1
SCHEMBL5416779 0.85 TBXAS1 (0.44) HTTKMT2AALOX5AP
SCHEMBL5405354 0.85 TSHR (0.47) HCRTR1HCRTR2KDM4EPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB HCRTR1 2878/4885HCRTR2 2515/4885KDM4E 4680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.